Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPY6IG)

Drug Name
QUIPAZINE Drug Info
Synonyms
quipazine; 4774-24-7; 2-(piperazin-1-yl)quinoline; 2-Piperazin-1-yl-quinoline; 2-Piperazin-1-ylquinoline; Quinoline, 2-(1-piperazinyl)-; 2-(1-Piperazinyl)quinoline; Quipazine [INN]; 1-(2-Quinolinyl)piperazine; Quipazinum [INN-Latin]; Quipazina [INN-Spanish]; UNII-4WCY05C0SJ; 1-(2-Quinolyl)piperazine; 2-(1-Piperazinyl)chinolin; BRN 0196945; 4WCY05C0SJ; CHEMBL18772; 2-quinolylpiperazine; F3306-0004; Quipazinum; Quipazina; TPC-A004; MA-1291; Spectrum_001733; Tocris-0629; piperazin-1-yl-quinoline; AC1L1JEX; AC1Q4WAV; Spectrum4_001259
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5011
ChEBI ID
CHEBI:93368
CAS Number
CAS 4774-24-7
TTD Drug ID
DMPY6IG
VARIDT Drug ID
DR00969

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [7]
Eletriptan DMW649X Migraine 8A80 Approved [8]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [8]
Frovatriptan DM7RE8P Migraine 8A80 Approved [8]
Sumatriptan DMVYXR8 Cluster headache 8A81.0 Approved [9]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [10]
Almogran DM7I64Z Migraine 8A80 Approved [11]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [12]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [13]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [15]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [16]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [17]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [18]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [17]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [19]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [20]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [16]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [21]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Serotonin transporter (SERT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [23]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [24]
Fluoxetine DM3PD2C Bipolar depression Approved [8]
Vortioxetine DM6F1PU Major depressive disorder 6A70.3 Approved [25]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [26]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [27]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [28]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [8]
Nortriptyline DM4KDYJ Depression 6A70-6A7Z Approved [8]
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [29]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [30]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [31]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [25]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [32]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [33]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [34]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [35]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [36]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 3B receptor (HTR3B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [38]
SEROTONIN DMOFCRY Discovery agent N.A. Investigative [4]
2-methyl-5-HT DM1S5CB N. A. N. A. Investigative [39]
MESULERGINE DMKGWAH Discovery agent N.A. Investigative [40]
bilobalide DM09Z35 Discovery agent N.A. Investigative [41]
2-(4-Methyl-piperazin-1-yl)-quinoline DMB8OY6 Discovery agent N.A. Investigative [4]
BRL-24682 DMSB4EW Discovery agent N.A. Investigative [42]
6-(4-Methyl-piperazin-1-yl)-phenanthridine DM1HAWR Discovery agent N.A. Investigative [4]
trichloroethanol DMNALMF Discovery agent N.A. Investigative [43]
1-phenylbiguanide DMA4XGL Discovery agent N.A. Investigative [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 3A receptor (HTR3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dolasetron DMMG26Z Nausea MD90 Approved [45]
Alosetron DML2A03 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [46]
Tropisetron DMNSJ7V Fibromyalgia MG30.01 Approved [47]
Palonosetron DMBHMOX Nausea MD90 Approved [48]
Levetiracetam DMTGDN8 Epilepsy 8A60-8A68 Approved [47]
Procaine DM4LSNE Anaesthesia 9A78.6 Approved [49]
Cilansetron DMP0NGX Irritable bowel syndrome DD91.0 Phase 3 [50]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [38]
Norcisapride DMJSKUI Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [51]
YM-114 DML2IXO Nausea MD90 Discontinued in Phase 2 [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [8]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [53]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [54]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [55]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [25]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [56]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [57]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [58]
Treximet DMU54QB Migraine 8A80 Approved [59]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [60]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Inhibitor [2]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Inhibitor [3]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [2]
5-HT 3A receptor (HTR3A) TTPC4TU 5HT3A_HUMAN Inhibitor [2]
5-HT 3B receptor (HTR3B) TTR6K75 5HT3B_HUMAN Inhibitor [4]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Inhibitor [5]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 173).
2 Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50.
3 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
4 Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
5 Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
6 Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62.
7 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
10 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
11 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
12 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 Company report (NeurAxon)
15 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
16 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
17 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
18 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
19 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
20 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
21 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
22 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
23 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
24 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
25 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
26 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
27 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
28 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
29 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
30 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
31 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
32 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
33 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
34 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
35 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
36 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
37 Clinical pipeline report, company report or official report of Lundbeck.
38 Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
39 The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature. 1999 Jan 28;397(6717):359-63.
40 Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. J Med Chem. 1997 Oct 24;40(22):3670-8.
41 Ginkgolide B and bilobalide block the pore of the 5-HT eceptor at a location that overlaps the picrotoxin binding site. Neuropharmacology. 2011 Feb-Mar;60(2-3):488-95.
42 Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
43 Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity. Brain Res Mol Brain Res. 2005 Dec 14;142(2):146-50.
44 Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
45 Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
46 Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
47 Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
48 Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
49 Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
50 Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
51 mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
52 Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.
53 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
54 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
55 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
56 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
57 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
58 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
59 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)